

1 **Long-term neutralizing antibody dynamics against SARS-CoV-2 in**  
2 **symptomatic and asymptomatic infections: a systematic review and**  
3 **meta-analysis**

4  
5 Wanying Lu<sup>1\*</sup>, Nan Zheng<sup>1\*</sup>, Xinhua Chen<sup>1</sup>, Ruijia Sun<sup>1</sup>, Jiayi Dong<sup>1</sup>, Shijia Ge<sup>2</sup>,

6 Xiaowei Deng<sup>1</sup>, Hongjie Yu<sup>1,3†</sup>

7  
8 1. Fudan University, Key Laboratory of Public Health Safety, Ministry of Education,  
9 Shanghai, China

10 2. Department of Infectious Diseases, Shanghai Key Laboratory of Infectious  
11 Diseases and Biosafety Emergency Response, National Medical Center for Infectious  
12 Diseases, Huashan Hospital, Fudan University, Shanghai, China

13 3. Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health,  
14 Fudan University, Shanghai, China

15  
16 \*Contributed equally as co-first authors

17 Corresponding author:

18 Hongjie Yu, E-mail: [yhj@fudan.edu.cn](mailto:yhj@fudan.edu.cn)

19  
20 Abstract: 314 words

21 Main text: 3,561 words

22 Running Title: Review of long-term neutralizing antibody dynamics against natural

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 SARS-CoV-2 infections

24

25 **Disclaimer:** The views expressed are those of the authors and do not necessarily

26 represent the institutions with which the authors are affiliated.

## 27 **Summary**

## 28 **Background**

29 The kinetics of the neutralizing antibody response against SARS-CoV-2 is crucial for  
30 responding to the pandemic as well as developing vaccination strategies. We aimed to  
31 fit the antibody curves in symptomatic and asymptomatic individuals.

## 32 **Methods**

33 We systematically searched PubMed, Embase, Web of Science, and Europe PMC for  
34 articles published in English between Jan 1, 2020, and Oct 2, 2022. Studies evaluating  
35 neutralizing antibody from people who had a natural SARS-CoV-2 infection history  
36 were included. Study quality was assessed using a modified standardized scoring  
37 system. We fitted dynamic patterns of neutralizing antibody using a generalized  
38 additive model and a generalized additive mixed model. We also used linear  
39 regression model to conduct both univariate and multivariable analyses to explore the  
40 potential affecting factors on antibody levels. This study is registered with  
41 PROSPERO, CRD42022348636.

## 42 **Results**

43 7,343 studies were identified in the initial search, 50 were assessed for eligibility after  
44 removal of duplicates as well as inappropriate titles, abstracts and full-text review,  
45 and 48 studies (2,726 individuals, 5,670 samples) were included in the meta-analysis  
46 after quality assessment. The neutralization titer of people who infected with SARS-  
47 CoV-2 prototype strain peaked around 27 days (217.4, 95%CI: 187.0-252.9) but  
48 remained below the Omicron BA.5 protection threshold all the time after illness onset

49 or confirmation. Furthermore, neither symptomatic infections nor asymptomatic  
50 infections could provide over 50% protection against Omicron BA.5 sub-lineage. It  
51 also showed that the clinical severity and the type of laboratory assays may  
52 significantly correlated with the level of neutralizing antibody.

### 53 **Conclusions**

54 This study provides a comprehensive mapping of the dynamic of neutralizing  
55 antibody against SARS-CoV-2 prototype strain induced by natural infection and  
56 compared the dynamic patterns between prototype and variant strains. It suggests that  
57 the protection probability provided by natural infection is limited. Therefore, timely  
58 vaccination is necessary for both previously infected symptomatic and asymptomatic  
59 individuals.

60

### 61 **Key words**

62 COVID-19; SARS-CoV-2; natural infection; neutralizing antibodies; dynamic;  
63 symptomatic; asymptomatic

## 64 **Introduction**

65 Corona Virus Disease 2019 (COVID-19) is an acute respiratory infectious diseases  
66 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Parts of  
67 COVID-19 patients develop symptoms such as fever, cough, and headache, but more  
68 individuals may show no symptoms all the time. These asymptomatic individuals  
69 account for a larger proportion yet they are harder to be found<sup>1</sup>. From the first  
70 outbreak in 2020 to the present, over 615 million cases have been caused<sup>2</sup> and the  
71 pathogen, has undergone several mutations and derives many variants over time as  
72 well. WHO has paid special attention to Alpha (B.1.1.7), Beta (B.1.351), Gamma  
73 (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529), which has been listed as Variants of  
74 Concern (VOCs)<sup>3</sup>. In January 2022, Omicron BA.1 sub-lineage was taking over the  
75 Delta variant and becoming dominant globally. Gradually, BA.2 and its constituent  
76 sub-lineages, such as BA.2.12.1, are overtaking BA.1 as the dominant variant globally.  
77 More recent two sub-lineages BA.4 and BA.5 gradually became prevalent since June  
78 2022, with the BA.5 being the dominantly circulating strains around the world.  
79 Existing evidence suggests that there are more than 60  
80 substitutions/deletions/insertions in Omicron<sup>4</sup>, with fifteen mutations located in the  
81 receptor binding domain (RBD), a region that mediates virus attachment to the  
82 angiotensin converting enzyme 2 (ACE2) receptor on target cells and is the principal  
83 target of neutralizing antibody that contributes to protection against SARS-CoV-2<sup>5,6</sup>.  
84 These mutations give Omicron variant increased transmissibility and enhance its  
85 immune-escape ability, which made it the major circulating variant currently<sup>3</sup>.

86

87 After infected with SARS-CoV-2, individuals produce neutralizing antibody, which is  
88 part of the humoral response and prevents the interaction of infectious particles with  
89 host cells by interfering with virion binding to receptors and blocking virus uptake  
90 into host cells<sup>7</sup>. Therefore, neutralizing antibody produced in infected individuals may  
91 protect them from reinfection to a certain extent. In other words, neutralizing antibody  
92 is likely to be a key correlate of immune protection<sup>8</sup>. However, neutralizing antibody  
93 level may be affected by age and clinical severity, and as neutralizing antibody titer  
94 declines over time, its protection diminishes as well<sup>9</sup>. When neutralizing antibody  
95 drop below a certain level, reinfection may occur<sup>10</sup>. To maintain effective neutralizing  
96 antibody levels, vaccination is a good way. For the general population, a booster dose  
97 or even a fourth dose is recommended nowadays. However, for individuals who have  
98 ever been infected, only a few countries have defined clear vaccination strategies and  
99 these strategies differ a lot across settings. For example, China recommends COVID-  
100 19 convalescents to vaccinate one dose six months after infection<sup>11</sup>, while the United  
101 States recommends delaying the next dose for three months after infection<sup>12</sup>.

102

103 Considering the limited vaccine resources and the fairness of distribution, when and  
104 how to vaccinate are urgent issues for COVID-19 convalescents, which requires  
105 studies on antibody kinetics and immune protection in natural SARS-CoV-2  
106 infections. At present, there are few reviews that quantitatively and comprehensively  
107 summarized the long-term dynamics of neutralizing antibody titer in COVID-19

108 convalescents or asymptomatic infections, neither for prototype strain nor for other  
109 variants. The existing systematic reviews and meta-analysis are based on limited  
110 numbers of studies, which make the summary of the antibody kinetics limited to the  
111 first few months after infection and lack comparability between different virus  
112 neutralization assays<sup>13-16</sup>.

113

114 In this study, we systematically collected data on time-varying neutralizing antibody  
115 from people who had a natural SARS-CoV-2 infection history, including symptomatic  
116 COVID-19 convalescents and asymptomatic infections. Based on collected data, we  
117 fitted dynamic patterns of neutralizing antibody using a generalized additive model  
118 (GAM) and a generalized additive mixed model (GAMM), estimated the peak times  
119 and detectable duration and explored the potential effects that age group, clinical  
120 severity and neutralization assays on antibody levels using both univariate and  
121 multivariable analyses. We also compared the differences showed in kinetic patterns  
122 between the prototype strain and variants.

123

## 124 **Methods**

### 125 **Search strategy and selection criteria**

126 According to the Preferred Reporting Items for Systematic Reviews and Meta-  
127 Analyses protocols<sup>17</sup>, we systematically did a literature review from three peer-  
128 reviewed databases (PubMed, Embase, and Web of Science) and one preprint server  
129 (Europe PMC). The key search terms used were as follows: “SARS-CoV-2”,

130 “neutralizing antibody”, “dynamic”, “kinetics”, “symptomatic”, and “asymptomatic”.

131 Detailed search terms were listed in **Supplementary Table 1**. Two independent  
132 researchers (WL, NZ) assessed all retrieved papers published in English from Jan 1,  
133 2020 to Oct 2, 2022. A third researcher (XC) was consulted when the two reviewers  
134 disagreed on study assessment. We included studies that reported neutralizing  
135 antibody against SARS-CoV-2 prototype or variant strains by using serum or plasma  
136 collected from symptomatic and asymptomatic individuals with virologically or  
137 serologically-confirmed SARS-CoV-2 infections. Studies that investigated  
138 immunogenicity among specific population, such as pregnant women, cancer people,  
139 immunodeficient patients, would be excluded. Detailed inclusion and exclusion  
140 criteria were listed in **Supplementary Table 2**. This study was registered with  
141 PROSPERO (no. CRD42022348636).

142

### 143 **Quality assessment**

144 Based on the Newcastle–Ottawa Scale (NOS)<sup>18</sup> scoring system recommended by the  
145 Cochrane Collaboration, we developed a revised scoring system to assess the study  
146 quality. We comprehensively assessed study design (e.g., clear criteria and definition),  
147 laboratory assay (e.g., validated neutralization assay), and outcome interpretation (e.g.,  
148 clear definition of sampling time) for each included study. The scoring system has a  
149 total of nine items, with one point assigned for each item. A score of 0–3 was  
150 considered a low-quality (grade C) study, a score of 4–6 was considered a moderate-  
151 quality (grade B) study, and a score of 7–9 was considered a high-quality (grade A)



152 study Detailed scoring system were listed in **Supplementary Table 3**. Only high and  
153 moderate-quality literatures were included in this study.

154

#### 155 **Data extraction**

156 For eligible studies, two researchers (WL, NZ) extracted the following data using a  
157 standardized electronic data collection form: published journal or preprints servers,  
158 title, first author's name, study location, study design, study participants, sample sizes,  
159 sampling time, age, sex, race, ethnicity, underlying conditions, clinical severity,  
160 details of laboratory testing methods including neutralization assays used, sample type  
161 (sera or plasma), and other factors that may affect the serological results, such as  
162 dilution factor, number of duplicates, cell line, virus titer used in the assay and the  
163 individual antibody titer that neutralizes or inhibits 50% of the virus(e.g., NT<sub>50</sub>,  
164 PRNT<sub>50</sub>). For each included study, we summarized its study participants, laboratory  
165 methods, and outcome in **Supplementary Table 4**. Pre-trained researchers digitized  
166 individual titer values from the figures in articles if titer were not available in table  
167 format<sup>19</sup>. We made reliable assumptions according to the information of the locally  
168 circulating viruses and the time when the variants begin to circulate in the region if  
169 the exact virus lineage causing the infection for some participants is unknown.  
170 Besides, if key information, such as the details of laboratory testing method, was not  
171 reported in the paper, we will contact the corresponding author via email for data  
172 inquiry. For those individuals with titer lower than limit of detection, we assumed a  
173 titer half that limit (e.g., a titer of 10 is assumed when "<20" was present)<sup>20</sup>. For those

174 individuals with titer higher than limit of detection, we assumed a titer that limit (e.g.,  
175 a titer of 1024 is assumed when “>1024” was present).

176

### 177 **Data classification and synthesis**

178 We classified multiple neutralization assays used in included studies into three  
179 categories based on the type of virus (live or pseudo) used and the types of vectors  
180 (lentivirus or vesicular stomatitis virus [VSV]) used in pseudovirus neutralization  
181 assays: live virus neutralization assays, lentivirus-vector pseudovirus neutralization  
182 assays, and VSV-vector pseudovirus neutralization assays. In each category of assay,  
183 we further stratified study participants into two groups based on the presence or  
184 absence of symptoms: (1) symptomatic individual<sup>21</sup>: a symptomatic individual is one  
185 with laboratory-confirmed SARS-CoV-2 infection as determined by PCR and/or  
186 serology and with symptoms including but not limited to fever, cough, general  
187 weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea,  
188 anorexia/nausea/vomiting, diarrhea. (2) asymptomatic individual<sup>22</sup>: an asymptomatic  
189 individual is one with laboratory-confirmed SARS-CoV-2 infection as determined by  
190 PCR and/or serology but with no symptoms whatsoever for the duration of infection.  
191 The characteristics of the participants (e.g., age, clinical severity and comorbidities)  
192 were defined as follows. We divided the ages into three groups:  $\leq 15$ , 16-60 and  $>60$ .  
193 As for clinical severity in symptomatic cases, we distinguished between mild and  
194 severe individuals according to the World Health Organization<sup>23</sup> and National  
195 Institutes of Health<sup>24</sup>. Standards were as follows: (1) severe case: the patient were

196 categorized into severe cases if they were attended to Intensive Care Unit (ICU),  
197 received oxygen supplementation (decreased oxygen saturation ( $\leq 94\%$ )), ventilation  
198 treatment during the hospitalization, or developing of pneumonia. (2) mild case:  
199 symptomatic but not severe case was classified as mild case. For comorbidities, we  
200 only distinguished whether they have comorbidities instead of what or how many  
201 comorbidities there were.

202

### 203 **Data analysis**

204 Titer of symptomatic and asymptomatic infection-induced SARS-CoV-2 neutralizing  
205 antibody were log-transformed before data analysis. Model fitting was carried out  
206 according to the types of virus strains, which confirmed by article report or gene  
207 sequencing. A generalized additive model with Gaussian distribution that allows for  
208 flexible specification of dependence of response to covariates was used to fit the  
209 kinetics of SARS-CoV-2 neutralizing antibody. The model was shown in Equation 1:

$$210 \quad g[E(y_i)] = \alpha + \beta s(x_i) + \varepsilon, \quad (1)$$

211 Where  $E(y_i)$  is mean neutralizing antibody titer against SARS-CoV-2,  $g$  is the log  
212 link function,  $\alpha$  is the intercept,  $s(x_i)$  is the value at a given time  $x_i$  of a smoothing  
213 spline basis,  $\beta$  is the vector of spline coefficient, and  $\varepsilon$  is the random error.

214

215 Considering of the individual random effects, we also presented a subset of matched  
216 data of which sera were consecutively collected from the same individual, using

217 generalized additive mixed model to model the dynamic curves. We assumed the  
218 Gaussian distribution of neutralizing antibody titer in symptomatic individuals while  
219 Gamma distribution in asymptomatic individuals based on the type of distribution.  
220 The specification for the GAMM smoothing model is defined as follows:

$$221 \quad g[E(y_i)] = \alpha + \beta s(x_i) + Z_b + \varepsilon, \quad (2)$$

222 Where  $Z_b$  is the random effect. Comparisons between models were made based on  
223 Bayesian information criteria (BIC) and Akaike information criteria (AIC). Besides,  
224 we determined prototype strain and Omicron BA.5 sub-lineage protective threshold  
225 which defined as 50% protective neutralization level against virus infections based on  
226 previous studies<sup>25,26</sup>.

227

228 We used linear regression model to conduct both univariate and multivariable  
229 analyses. The factors included age, sex, comorbidity, clinical severity and assays. For  
230 all statistical tests, a two tailed p value of less than 0.05 was considered statistically  
231 significant. We also compared the neutralizing antibody dynamic curves among  
232 different virus strains based on the same laboratory assay and clinical severity. All  
233 statistical analyses were done using R software (version 4.2.0).

234

## 235 **Results**

### 236 **Study selection and data extraction**

237 We identified a total of 4,550 studies after systematically searching multiple data

238 sources with 1,966 coming from peer-reviewed databases, and 2,584 from preprint  
239 server (**Figure 1**). After screening titles, abstracts, and full-texts, 50 studies containing  
240 a total of 2,726 individuals and 5,783 samples were included. After quality assessment,  
241 there were 18 grade A (18/50, 36%), 30 grade B (30/50, 60%) and 2 grade C studies  
242 (2/50, 4%), and studies classified as grade A and B were included into analysis  
243 (**Figure S1, Table S5**). Among 48 studies, with prototype strain infections the  
244 subjects accounted for the most (47 studies; 5,546 of 5,670 samples, 97.8%), followed  
245 by Alpha strain infected individuals (2 studies; 110 of 5,670 samples, 1.9%) and  
246 Omicron BA.2 sub-lineage infections (1 study; 14 of 5,670 samples, 0.2%). Live virus  
247 neutralization assays were most common (27 of 48 studies, 56.3%), followed by  
248 lentivirus-vector pseudovirus neutralization assays (15 of 48 studies, 31.2%) and  
249 VSV-vector pseudovirus neutralization assays (6 of 48 studies, 12.5%). Most  
250 participants were symptomatic cases (46 studies; 2,480/2,690 individuals, 92.2%;  
251 5,281/5,670 samples, 93.1%), while asymptomatic individuals accounted for a  
252 relatively small proportion (12 studies; 210/2,690 individuals, 7.8%; 389/5,670  
253 samples, 6.9%).

254

### 255 **Antibody responses in prototype strain infections in live virus neutralization** 256 **assays**

257 For the overall dynamic curve fitted with matched sera, titer peaked around 27 days  
258 (217.4, 95%CI: 187.0-252.9) after illness onset or confirmation. It remained above the  
259 detection limit of 10 after 479 days, dropped below the prototype strain protection

260 threshold (19) at day 467 after illness onset or confirmation and kept below the  
261 Omicron BA.5 protection threshold (266) all the time (**Figure 2A**). As for the  
262 dynamic curve in symptomatic and asymptomatic infections separately, antibody titer  
263 of symptomatic convalescents peaked around 26 days (250.8, 95%CI: 214.8-292.7)  
264 after illness onset, then declined (**Figure 2B**). Antibody titer of asymptomatic  
265 individuals were consistently lower than that of symptomatic convalescents all the  
266 time. It took 463 and 171 days for neutralization titer to drop to the prototype strain  
267 protection threshold (19) respectively in symptomatic individuals and asymptomatic  
268 individuals but both of them remained below the Omicron BA.5 protection threshold  
269 (266) and above the detection limit of 10 during the whole follow-up period (**Figure**  
270 **2C**). Results of all samples showed similarity to those of paired sera, with slight  
271 difference mainly in the timing of peak and protection thresholds (**Figure S2**).

272

### 273 **Association between clinical outcomes and antibody responses in prototype** 274 **strain infections**

275 In the univariate analyses, the levels of neutralizing antibody increased over age, with  
276 the mean neutralization level of 47.9, 137.6 and 209.2 in the groups of  $\leq 15$  years, 15-  
277 60 years and  $> 60$  years, respectively (**Figure 3, Table S6**). For different clinical  
278 endpoints, the neutralization titer in mild cases was significantly higher than that of  
279 asymptomatic individuals, but lower than that of severe cases ( $p < 0.001$ ). The levels of  
280 neutralizing antibody varied in the types of neutralization assays, with the neutralizing  
281 antibody tested by lentivirus-vector pseudovirus neutralization assays had the highest

282 titer, followed by VSV-vector pseudovirus and live virus neutralization assays. In the  
283 multivariable analysis, after controlling potential biases, only clinical severity and  
284 types of neutralization assays were statistically significant.

285

### 286 **Comparison of neutralizing antibody responses between prototype strain and** 287 **variants**

288 There are few eligible studies explore the antibody kinetics in individuals infected  
289 with variants, with only two studies for Alpha and one study for Omicron BA.2.  
290 Considering the limited number of sample size, heterogeneity of study design, as well  
291 as different antibody detection method, we compare the pattern rather than the  
292 antibody level between prototype strain and variants. As for the comparison between  
293 prototype and Alpha strains infections in lentivirus-vector pseudovirus neutralization  
294 assays, individual antibody titer was fitted up to 180 days and 122 days for prototype  
295 strain and Alpha strain, respectively. Overall, although the follow-up period was  
296 shorter in the study of Alpha variant, the dynamic patterns of the both were similar  
297 based on matched samples. Antibody titer of Alpha convalescents peaked around 33  
298 days after symptom onset, while peaked around day 28 in prototype convalescents. It  
299 kept waning for the next 90 days without signs of plateauing. Up to day 122 after  
300 symptom onset, the antibody level of Alpha strain remained higher than that of the  
301 prototype strain (**Figure 4**). As for the comparison between prototype strain and  
302 Omicron BA.2 sub-lineage infections in live virus neutralization assays, matched  
303 individual antibody titer was available for up to 209 days and 52 days for prototype

304 strain and Omicron BA.2 sub-lineage, respectively. Antibody titer of Omicron BA.2  
305 peaked at day 39, 10 days later than that of prototype convalescents, then showed a  
306 downward trend Due to the short follow-up period of the Omicron BA.2 study, it was  
307 difficult to compare the complete dynamic patterns with the prototype strain.

308

## 309 **Discussion**

310 Our study systematically retrieved the data of neutralizing antibody titers in naturally  
311 infected individuals, fitted the dynamic curves, and explored the factors associated  
312 with antibody levels. We also compared antibody responses between prototype and  
313 variant strains. We found neutralization titer peaked around 27 days (217.4, 95%CI:  
314 187.0-252.9) after illness onset or confirmation but remained below the Omicron  
315 BA.5 protection threshold all the time after illness onset or confirmation. Furthermore,  
316 neither symptomatic infections nor asymptomatic infections could provide over 50%  
317 protection against Omicron BA.5 sub-lineage. Our results also showed that the  
318 clinical severity and the type of laboratory assays may significantly correlated with  
319 the level of neutralizing antibody.

320

321 Our study showed that neutralizing antibody in natural infection individuals could be  
322 detected at around 2 days after confirmation or onset of symptoms, peaked around 27  
323 days, and then started to decline. The antibody level remained detectable (>1:10) for  
324 at least 16 months, which was consistent with previous studies that showed that  
325 neutralizing antibody could be detected at around 6-15 days after infection<sup>27</sup>, reached



326 peak around 31-45 days<sup>28</sup>, then started to decline<sup>14,16</sup>, and remained near the detection  
327 limit at around 360 days<sup>29</sup>. As for the asymptomatic infections, we did not observe a  
328 marked increase of antibody level during the acute phase. Since asymptomatic  
329 individuals remain asymptomatic from exposure to infection and virus expulsion,  
330 these individuals are often difficult to be captured by symptom-based surveillance. In  
331 addition, because individuals are asymptomatic all the time, they usually do not  
332 initiate to seek assistance in medical institutions, which increases the difficulty of  
333 early identification of asymptomatic individuals. Most of the studies included in this  
334 study were hospital-based follow-up studies, so it was very hard to identify  
335 asymptomatic individuals in the early stage of exposure, nor to better quantify the  
336 trend of rapidly increasing neutralizing antibody levels during this period. As for the  
337 dynamic patterns of variant strains, we did not compare the antibody levels  
338 considering the heterogeneity between studies, such as characteristic of participants  
339 and laboratory assays. We only compared the dynamic curves, which were similar to  
340 the patterns of prototype strain. Long-term follow-up studies are needed to determine  
341 the dynamic curves of the variant strains.

342

343 In our study, we found neutralization titer remained under the Omicron BA.5  
344 protection threshold all the time after confirmation. A test-negative, case-control  
345 study showed that the protection probability against Omicron BA.5 infection and  
346 symptomatic infection was 33.5% (95% CI: 29.3-37.5%) and 38.1% (95% CI: 27.7-  
347 46.9%) separately at 493 and 496 days after infection in individuals who previously

348 infected pre-omicron strain<sup>30</sup>. Another study, which estimated the protection effect in  
349 a population with hybrid immunity (previous infection and vaccination), showed that  
350 the protection effect against BA.5 infection was 51.6% (95% CI: 50.6-52.6%) in  
351 Wuhan-Hu-1 strain infected individuals<sup>31</sup>. Results of these studies suggested that the  
352 antibody level after natural infection with the prototype strain could not provide 50%  
353 protection probability against Omicron BA.5 infection, which were similar to that of  
354 our study. So the COVID-19 vaccines should be administered as soon as possible to  
355 obtain effective protection. Like a special “infection”, the COVID-19 vaccine  
356 effectiveness or efficacy against the prototype strain are often compared with the  
357 protection probability of natural infection. One study showed that the effectiveness  
358 against BA.5 hospitalization was 47.4% (19.9-65.5%) within 3-4 months and 19.3%  
359 (6.3-30.5%) over 9 months<sup>32</sup>. The effectiveness against BA.5 infection would be  
360 lower<sup>25</sup>. It was similar to our study, suggesting that neutralizing antibody levels in  
361 naturally infected individuals as well as primary vaccinated population may not  
362 provide 50% protection probability against BA.5. This was consistent with previous  
363 study that showed the probability of protection after natural infection was similar to  
364 the effectiveness of two doses vaccination<sup>33</sup>.

365

366 Our study showed that neutralizing antibody levels are positively correlated with  
367 clinical severity, which was consistent with previous study<sup>34</sup> Since inflammatory  
368 cytokines may be related to higher levels of neutralizing antibody in severe cases.  
369 Severe cases tend to have high systemic level of pro-inflammatory cytokines, which

370 has been shown to correlate with antibody levels to COVID-19<sup>35</sup>. Moreover,  
371 inflammatory cytokines are closely related to humoral immunity, and studies have  
372 shown that IFN- $\gamma$ <sup>36</sup>, IL-12<sup>37</sup>, and IL-17<sup>38</sup> play important roles in B-cell development.  
373 Age was statistically significant in univariate analysis, indicating older age was  
374 associated with higher neutralizing antibody levels, but not in multivariate analysis.  
375 This could be because there were more severe cases in the elderly population, and  
376 clinical severity is positively correlated with neutralizing antibody levels, so antibody  
377 levels are higher in the elderly population.

378

379 Our study had several limitations. First, there were heterogeneity among the studies,  
380 but we minimized them by conducting subgroup analyses according to the population  
381 characteristic and laboratory assays. Second, the exact virus lineage causing the  
382 infection for some participants is unknown. However, we have made reliable  
383 assumptions according to the information of the local circulating viruses and the time  
384 when the variants began to circulate in the region. Third, relatively fewer sera beyond  
385 200 days after onset of illness was collected to define the late antibody waning  
386 kinetics. We also have relatively fewer numbers of asymptomatic infections compared  
387 to those with symptomatic disease. Thus, our findings on asymptomatic infections  
388 need to be interpreted with caution. Studies on the long-term dynamic changes of  
389 antibody in asymptomatic infected patients should be strengthened in the future.

390

391 In conclusion, our study provided a comprehensive mapping of the dynamic of

392 neutralizing antibody against SARS-CoV-2 prototype strain induced by natural  
393 infection and compared the dynamics between prototype and variant strain. Our  
394 findings suggested that the antibody level of symptomatic cases reached peak level at  
395 day 26 and then decreased, but it failed to provide 50% protection probability against  
396 Omicron BA.5, same as that of asymptomatic individuals. At present, the key  
397 question is to study the long-term dynamic changes of antibody after natural infection  
398 of mutant strains so as to understand when and how to vaccinate COVID-19  
399 convalescents, whether widespread immunization would lead to a temporary drop in  
400 morbidity, and how long it would take for another major outbreak to occur.

401

#### 402 **Acknowledgements**

403 This study was supported by grants from the Key Program of the National Natural  
404 Science Foundation of China (grant 82130093 to H.Y.).

405 **References**

- 406 1. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with  
407 SARS-CoV-2: a systematic review and meta-analysis. *The Lancet Global Health* 2021;  
408 **9**(5): e598-e609.
- 409 2. WHO. WHO Coronavirus (COVID-19) Dashboard. 2022.
- 410 3. WHO. Tracking SARS-CoV-2 variants. 2022.
- 411 4. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant:  
412 Characteristics and prevention. *MedComm (2020)* 2021; **2**(4): 838-45.
- 413 5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,  
414 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A  
415 Review. *JAMA* 2020; **324**(8): 782-93.
- 416 6. Starr TN, Greaney AJ, Hilton SK, et al. Deep Mutational Scanning of SARS-  
417 CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.  
418 *Cell* 2020; **182**(5): 1295-310 e20.
- 419 7. Pang NY-L, Pang AS-R, Chow VT, Wang D-Y. Understanding neutralising  
420 antibodies against SARS-CoV-2 and their implications in clinical practice. *Military*  
421 *Medical Research* 2021; **8**(1): 47.
- 422 8. Addetia A, Crawford Katharine HD, Dingens A, et al. Neutralizing Antibodies  
423 Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel  
424 Outbreak with a High Attack Rate. *Journal of Clinical Microbiology* 2020; **58**(11):  
425 e02107-20.
- 426 9. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-

- 427 CoV-2 infections. *Nature communications* 2021; **12**(1): 63.
- 428 10. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of  
429 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested  
430 individuals in Denmark in 2020: a population-level observational study. *The Lancet*  
431 2021; **397**(10280): 1204-12.
- 432 11. Group CCfDCaPC-VW. COVID-19 Vaccination Technical Guidelines (First  
433 Edition). 2021.
- 434 12. Prevention CfDcA. Getting a COVID-19 Vaccine. 2022.
- 435 13. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of  
436 antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and  
437 association with severity. *Nature communications* 2020; **11**(1): 4704.
- 438 14. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in  
439 humans: A systematic review. *PLOS ONE* 2021; **15**(12): e0244126.
- 440 15. Borremans B, Gamble A, Prager KC, et al. Quantifying antibody kinetics and  
441 RNA detection during early-phase SARS-CoV-2 infection by time since symptom  
442 onset. *Elife* 2020; **9**.
- 443 16. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody Response After  
444 SARS-CoV-2 Infection and Implications for Immunity. *Annals of Internal Medicine*  
445 2021; **174**(6): 811-21.
- 446 17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic  
447 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews*  
448 2015; **4**(1): 1.

- 449 18. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for  
450 assessing the quality of nonrandomised studies in meta-analyses. Accessed 31 July  
451 2022. [https://www.ohri.ca//programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp).
- 452 19. WebPlotDigitizer 4.5. [https://apps.automeris.io/wpd/index.zh\\_CN.html](https://apps.automeris.io/wpd/index.zh_CN.html) (accessed  
453 2022/08/28).
- 454 20. Chen X, Chen Z, Azman AS, et al. Neutralizing Antibodies Against Severe Acute  
455 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural  
456 Infection or Vaccination: A Systematic Review and Pooled Analysis. *Clinical*  
457 *infectious diseases : an official publication of the Infectious Diseases Society of*  
458 *America* 2022; **74**(4): 734-42.
- 459 21. World Health Organization. WHO COVID-19: Case Definitions. 2020.  
460 [https://www.who.int/publications/i/item/WHO-2019-nCoV-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2)  
461 [Surveillance\\_Case\\_Definition-2020.2](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2) (accessed 2020/12/16).
- 462 22. Meyerowitz EA, Richterman A, Bogoch, II, Low N, Cevik M. Towards an  
463 accurate and systematic characterisation of persistently asymptomatic infection with  
464 SARS-CoV-2. *The Lancet Infectious diseases* 2021; **21**(6): e163-e9.
- 465 23. World Health Organization. Clinical management of COVID-19: Living  
466 guideline, 23 June 2022. 2022. [https://www.who.int/publications/i/item/WHO-2019-](https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2022-1)  
467 [nCoV-clinical-2022-1](https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2022-1) (accessed 2022/6/23).
- 468 24. National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. 2021.  
469 <https://www.covid19treatmentguidelines.nih.gov/> (accessed 2021/10/19).
- 470 25. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly

- 471 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*  
472 *medicine* 2021; **27**(7): 1205-11.
- 473 26. Cheng SS, Mok CK, Li JK, et al. Plaque-neutralizing antibody to BA.2.12.1,  
474 BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines,  
475 natural infection and breakthrough infection. *Journal of clinical virology : the official*  
476 *publication of the Pan American Society for Clinical Virology* 2022; **156**: 105273.
- 477 27. Koblichke M, Traugott MT, Medits I, et al. Dynamics of CD4 T Cell and  
478 Antibody Responses in COVID-19 Patients With Different Disease Severity.  
479 *Frontiers in medicine* 2020; **7**: 592629.
- 480 28. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses  
481 to SARS-CoV-2 spike antigens in COVID-19 patients. *Science immunology* 2020;  
482 **5**(52).
- 483 29. Lin Y, Zhu J, Liu Z, et al. Kinetics of severe acute respiratory syndrome  
484 coronavirus 2 infection antibody responses. *Frontiers in immunology* 2022; **13**:  
485 864278.
- 486 30. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective Effect of Previous  
487 SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. *The New*  
488 *England journal of medicine* 2022.
- 489 31. Malato J, Ribeiro RM, Leite PP, et al. Risk of BA.5 Infection among Persons  
490 Exposed to Previous SARS-CoV-2 Variants. *The New England journal of medicine*  
491 2022; **387**(10): 953-4.
- 492 32. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness



- 493 and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South  
494 Africa. *The New England journal of medicine* 2022; **387**(14): 1332-3.
- 495 33. Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2  
496 reinfections: Overview of efficacy and duration of natural and hybrid immunity.  
497 *Environmental research* 2022; **209**: 112911.
- 498 34. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising  
499 antibody responses and duration of immunity: a longitudinal study. *The Lancet*  
500 *Microbe* 2021; **2**(6): e240-e9.
- 501 35. Wu F, Liu M, Wang A, et al. Evaluating the Association of Clinical  
502 Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered  
503 From Mild COVID-19 in Shanghai, China. *JAMA internal medicine* 2020; **180**(10):  
504 1356-62.
- 505 36. Abed NS, Chace JH, Fleming AL, Cowdery JS. Interferon-gamma regulation of  
506 B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-  
507 mediated inhibition of B cell differentiation. *Cellular immunology* 1994; **153**(2): 356-  
508 66.
- 509 37. Metzger DW. Interleukin-12 as an adjuvant for induction of protective antibody  
510 responses. *Cytokine* 2010; **52**(1-2): 102-7.
- 511 38. Shibui A, Shimura E, Nambu A, et al. Th17 cell-derived IL-17 is dispensable for  
512 B cell antibody production. *Cytokine* 2012; **59**(1): 108-14.
- 513

514 **Figure legends**

515 **Figure 1 Flowchart of study selection**

516 Flowchart of the selection of studies including time-varying neutralizing antibody  
517 data from Jan 1, 2020, to Oct 2, 2022.

518

519 **Figure 2 Neutralizing antibody responses in prototype strain infections in live**  
520 **virus neutralization assays**

521 A) All individuals; B) Symptomatic individuals; C) Asymptomatic individuals. Black  
522 lines represent detection limit (10); green lines, prototype strain protection threshold  
523 (19); blue lines, Omicron BA.5 protection threshold (266).

524

525 **Figure 3 Neutralizing antibody responses in prototype strain infections among**  
526 **different characteristics**

527 A) Age; B) Sex; C) Comorbidity; D) Clinical severity; E) Assay.

528


529 **Figure 4 Comparison of neutralizing antibody responses between prototype**  
530 **strain and variants**

531 A) Prototype and Alpha strains; B) Prototype strain and Omicron BA.2 sub-lineage.  
532 Black lines represent detection limit of prototype strain (10); red line, detection limit  
533 of Alpha strain (60); blue line, detection limit of Omicron BA.2 sub-lineage (20).

534

535


536 **Figure 1**



537

538


539 **Figure 2**



540

541


542 **Figure 3**



543

544

545 **Figure 4**



546